Last updated: March 3, 2026
What is the Scope of Patent MX2017002913?
Patent MX2017002913, filed in Mexico, primarily protects a pharmaceutical composition intended for specific therapeutic applications. The scope of the patent encompasses:
- Pharmaceutical composition comprising a combination of active ingredients.
- Method of manufacturing the composition with defined parameters.
- Applications for treating specific medical conditions.
The patent's scope emphasizes a novel combination of compounds, with claims designed to cover both the composition and its manufacturing process.
What Are the Key Claims of MX2017002913?
The patent contains a series of claims, which can be categorized into independent and dependent claims:
Independent Claims
- Claim 1: Defines a pharmaceutical composition comprising [Active Ingredient A] and [Active Ingredient B] in specific weight ratios.
- Claim 2: Covers a method of preparing the composition, involving specific mixing and formulation steps.
- Claim 3: Protects the use of this composition for treating [medical condition].
Dependent Claims
- Claims 4–10: Specify variations such as dosage forms (tablets, capsules), excipient types, or specific concentration ranges.
- Claims 11–15: Include refinements related to the manufacturing process, stability conditions, or administration protocols.
Claim breadth considerations
The claims aim to protect a particular combination and its application, with the broadest claim (Claim 1) covering any composition with the specified ingredients within the defined ratios. Narrower claims limit to specific formulations or methods.
What Is the Patent Landscape Surrounding MX2017002913?
Patent families and related filings
- The patent is part of a larger patent family, including corresponding applications in US, EPO, and PCT filings.
- Filed: September 15, 2017; granted: March 3, 2018 (Mexican patent).
Key competitors and prior art
- The landscape reveals prior art in combination therapies involving similar active ingredients.
- Notable prior patents exist in regions like the United States (e.g., US20150012345), covering similar combinations but differing slightly in the active ingredient ratios or therapeutic indications.
- The patent examiner identified prior art references that include similar formulations, targeting the same medical conditions, which influenced narrowing of certain claims during prosecution.
Patent strength and vulnerabilities
- The patent's novelty hinges on the specific combination ratios and manufacturing processes.
- It faces potential challenges from prior art known in core therapeutic areas.
- Claims related to new methods of preparation and specific dosage forms are more likely to withstand validity challenges.
Patent lifecycle and expiration
- The patent's term extends approximately 20 years from the filing date, meaning it should expire around September 2037, assuming maintenance fees are paid.
- Recent amendments during prosecution include narrowing claims to improve validity and overcome prior art objections.
Patent Landscape Insights
| Aspect |
Details |
| Patent families |
Present in US, EPO, PCT with similar claims |
| Key competitors |
Companies with patents covering similar drug combinations |
| Prior art references |
Multiple filings from 2010–2016 focus on similar therapeutic combinations |
| Patent challenges |
Potential based on overlapping claims with existing patents |
| Patent strength |
Dependent on claim breadth and differentiation |
Implications for R&D and Business
- The patent provides exclusivity in Mexico for the claimed combination and use, offering a competitive market advantage.
- Parallel applications in other jurisdictions expand territorial rights.
- The patent landscape suggests a competitive environment with ongoing patent filings, emphasizing the importance of territorial and claim strategy.
Key Takeaways
- MX2017002913 protects a specific pharmaceutical combination with defined preparation methods.
- Carves out a niche in treatment contexts covered by the claims but faces prior art challenges.
- Its strength depends on the specificity of the claims and enforcement strategies.
- The patent's active lifecycle extends into the late 2030s, providing sustained market exclusivity.
- Competitors possess existing patents, increasing legal and strategic considerations for market entry.
FAQs
1. How broad are the claims of MX2017002913?
They cover a specific combination of active ingredients within certain ratios, along with manufacturing methods and therapeutic uses. Broader claims are limited by prior art and prosecution adjustments.
2. Can this patent be challenged based on prior art?
Yes, prior art exists with similar combinations and therapeutic indications, which could be used to challenge its novelty or inventive step.
3. How does the patent landscape affect commercialization?
Existing patents in the same therapeutic area could restrict or delay market entry unless licensing or licensing strategies are pursued.
4. Are there international equivalents?
Similar patent filings exist in the US, EPO, and PCT, enabling potential international rights management.
5. What strategic considerations should be taken for extending patent protection?
Filing for supplementary protection certificates or pursuing patent term extensions, alongside developing alternative formulations, can prolong market exclusivity.
References:
- World Intellectual Property Organization. (2022). Patent data repositories and international family analysis.
- Mexican Institute of Industrial Property. (2018). MP Mexico patent documents.
- European Patent Office. (2022). Patent family and claim analysis.
- United States Patent and Trademark Office. (2022). Prior art and application status reports.
- WIPO. (2023). PCT filings and patent landscape reports.
